Segment Reporting by divisions Audited

Sales

4,993.8

4,649.6

464.9

439.9

5,458.7

5,089.5

Royalty and commission income*

351.1

363.9

2.1

2.1

353.2

366.0

Total revenues

5,344.9

5,013.5

467.0

442.0

5,811.9

5,455.5

Gross margin

4,485.5

4,218.0

319.5

294.0

4,805.0

4,512.0

Marketing and selling expenses*

–1,719.1

–1,598.9

–213.4

–194.1

–1,932.5

–1,793.0

Administration expenses

–263.6

–278.9

–24.3

–24.7

–287.9

–303.6

Other operating expenses and income

–317.4

–107.8

–9.9

5.1

–327.3

–102.7

Research and development

–1,183.6

–1,074.4

–19.5

–16.8

–1,203.1

–1,091.2

Operating result

354.7

593.7

48.3

61.3

403.0

655.0

Exceptional items

–39.8

–354.0

–

–

–39.8

–354.0

Earnings before interest and tax (EBIT)

314.9

239.7

48.3

61.3

363.2

301.0

Net operating assets

10,015.9

10,355.9

336.0

325.9

10,351.9

10,681.8

Segment liabilities

–1,078.2

–972.1

–76.9

–62.6

–1,155.1

–1,034.7

Capital spending on property, plant and equipment

317.2

235.4

10.0

14.1

327.2

249.5

Investments in intangible assets

74.8

123.2

1.4

2.4

76.2

125.6

Depreciation

–749.6

–734.3

–9.5

–7.0

–759.1

–741.3

Impairment losses

–99.1

–338.8

–

–

–99.1

–338.8

Net cash flows from operating activities

1,250.7

926.8

58.0

45.6

1,308.7

972.4

Net cash flows from investing activities

–386.3

–373.1

–9.1

–40.0

–395.4

–413.1

Free cash flow

864.4

553.8

48.9

5.6

913.3

559.4

Underlying free cash flow

866.8

559.5

48.9

38.1

915.7

597.6

FCR in %

16.2

11.2

10.5

8.6

15.8

11.0

ROS in %

6.6

11.8

10.3

13.9

6.9

12.0

Liquid Crystals

Performance &
Life Science Chemicals

Chemicals

€ million

2009

2008

2009

2008

2009

2008

Sales

725.0

864.6

1,194.0

1,240.9

1,919.0

2,105.5

Royalty and commission income*

7.6

13.4

8.5

8.6

16.1

22.0

Total revenues

732.6

878.0

1,202.5

1,249.5

1,935.1

2,127.5

Gross margin

356.5

541.7

556.2

632.6

912.7

1,174.3

Marketing and selling expenses*

–27.6

–26.4

–311.9

–306.5

–339.5

–332.9

Administration expenses

–17.6

–17.6

–61.3

–69.9

–78.9

–87.5

Other operating expenses and income

7.4

–18.5

–29.5

–28.5

–22.1

–47.0

Research and development

–87.5

–84.8

–54.0

–58.4

–141.5

–143.2

Operating result

227.5

391.2

96.8

166.5

324.3

557.7

Exceptional items

–

–

11.8

–46.0

11.8

–46.0

Earnings before interest and tax (EBIT)

227.5

391.2

108.6

120.5

336.1

511.7

Net operating assets

837.4

944.3

1,120.0

1,127.7

1,957.4

2,072.0

Segment liabilities

–78.6

–98.2

–151.6

–173.6

–230.2

–271.8

Capital spending on property, plant and equipment

64.2

64.5

75.5

78.9

139.7

143.4

Investments in intangible assets

3.9

2.0

8.5

3.4

12.4

5.4

Depreciation

–62.0

–56.6

–71.6

–70.1

–133.6

–126.7

Impairment losses

–7.8

–0.6

–1.7

–6.1

–9.5

–6.7

Net cash flows from operating activities

359.7

472.7

207.9

146.5

567.6

619.2

Net cash flows from investing activities

–67.8

–70.6

–89.3

–88.8

–157.1

–159.4

Free cash flow

291.9

402.1

118.6

57.7

410.5

459.8

Underlying free cash flow

291.9

406.7

139.8

66.9

431.7

473.6

FCR in %

39.8

46.3

11.6

5.4

22.3

22.3

ROS in %

31.0

44.6

8.0

13.3

16.8

26.2

Corporate
and Other

Group

€ million

2009

2008

2009

2008

Sales

–

6.6

7,377.7

7,201.6

Royalty and commission income*

–

–

369.3

388.0

Total revenues

–

6.6

7,747.0

7,589.6

Gross margin

–

–2.7

5,717.7

5,683.6

Marketing and selling expenses*

–0.3

–2.3

–2,272.3

–2,128.2

Administration expenses

–58.1

–55.1

–424.9

–446.2

Other operating expenses and income

–23.3

–20.4

–372.7

–170.1

Research and development

–

–

–1,344.6

–1,234.4

Operating result

–78.4

–81.3

648.9

1,131.4

Exceptional items

–

–

–28.0

–400.0

Earnings before interest and tax (EBIT)

–78.4

–81.3

620.9

731.4

Net operating assets

37.4

14.4

12,346.7

12,768.2

Segment liabilities

–15.7

–10.2

–1,401.0

–1,316.7

Capital spending on property, plant and equipment

0.4

1.8

467.3

394.7

Investments in intangible assets

8.0

9.9

96.6

140.9

Depreciation

–1.9

–1.7

–894.6

–869.7

Impairment losses

–0.8

–0.1

–109.4

–345.6

Net cash flows from operating activities

–505.0

–567.6

1,371.3

1,024.0

Net cash flows from investing activities

–1,608.2

490.8

–2,160.7

–81.7

Free cash flow

–511.4

–580.8

812.4

438.4

Underlying free cash flow

–495.8

–469.9

851.6

601.3

FCR in %

–

–

11.0

7.9

ROS in %

–

–

8.4

14.9